Crystalline PC945 Polymorphs for Stable Inhaled Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antifungal compounds like Compound I face challenges in achieving effective topical administration to the lung due to poor crystalline forms, leading to low drug concentrations, stability issues, and resistance, which complicates the treatment of invasive fungal infections.
Innovation Solution
Development of crystalline polymorphic forms (Form 1 and Form 2) of Compound I, which exhibit high melting points, chemical stability, and are readily micronizable, ensuring bioavailability when administered as an aqueous suspension by inhalation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing antifungal compounds are administered orally or systemically, then the drug can reach the bloodstream, but the drug concentration at the site of infection in the lung is lower than in non-affected organs
Solution Approach 1:
The patent changes the physical state parameter of the compound from amorphous to crystalline polymorphic forms, which improves dissolution characteristics and bioavailability, thereby increasing drug concentration at the infection site while maintaining oral administration
Solution Approach 2:
The patent utilizes phase transition from amorphous to crystalline state to improve the drug's physicochemical properties. The crystalline polymorphic forms exhibit better stability and controlled dissolution, enabling effective topical administration to the lung with higher drug concentrations at the infection site
2Reliability
If oral triazole medicines are used to treat invasive aspergillosis, then the disease can be treated, but mortality rates remain high exceeding 50%
Solution Approach 1:
The patent changes the crystalline state parameters to develop polymorphic forms with improved dissolution and bioavailability, which enhances treatment efficacy and reduces mortality by ensuring adequate drug concentrations are achieved at the infection site
Solution Approach 2:
The patent performs preliminary development of optimized crystalline forms before clinical use, ensuring that the drug has optimal dissolution characteristics and bioavailability built-in, which prevents treatment failure and reduces mortality in invasive aspergillosis
3Use of energy by moving object
If the liver is exposed to antifungal drugs, then the drug can be metabolized, but significant drug interactions arise from inhibition of hepatic P450 enzymes
Solution Approach 1:
The patent changes the physicochemical parameters of the drug through crystalline form modification, improving dissolution and bioavailability. This allows for lower dosing requirements, which reduces hepatic P450 enzyme inhibition and minimizes drug interactions while maintaining effective metabolism
4Ease of manufacture
If amorphous forms of Compound I are used, then the compound can be synthesized, but the crystalline forms exhibit poor stability and low bioavailability
Solution Approach 1:
The patent utilizes phase transition from amorphous to crystalline state to improve stability. The crystalline polymorphic forms exhibit enhanced chemical and physical stability compared to amorphous forms, while maintaining manufacturability through controlled crystallization processes
Solution Approach 2:
The patent changes the physical state parameter from amorphous to crystalline, which fundamentally improves stability characteristics. The crystalline structure provides better molecular packing and intermolecular interactions, resulting in enhanced chemical and physical stability while preserving the compound's synthesizability
Data Source
AI summary
The invention relates to crystalline polymorphic manifestations of a compound of formula (I):and related aspects.